Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 10:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Thyroxine Clear all
Completed Phase 1 Interventional

Open-label Study of Liothyronine in MS

NCT02506751
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Interventions
liothyronine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 58 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2018 · Synced Sep 24, 2026, 10:49 PM EDT
Terminated Phase 4 Interventional

Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression

NCT00296686
View directory record Official record
Conditions
Major Depression
Interventions
Tranylcypromine, Dextroamphetamine, Triiodothyronine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2012 · Synced Sep 24, 2026, 10:49 PM EDT
Completed Phase 3 Interventional

Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.

NCT00158990
View directory record Official record
Conditions
Major Depression, Bipolar Disorder, Unipolar Depression
Interventions
triiodothyronine, sertraline
Drug
Lead sponsor
Hadassah Medical Organization
Other
Eligibility
18 Years to 70 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2007 · Synced Sep 24, 2026, 10:49 PM EDT
Terminated No phase listed Observational Results available

Study of Possible Brain Hormone Problems After Open Heart Surgery in Infants

NCT00850720
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Blood draws
Other
Lead sponsor
Emory University
Other
Eligibility
Up to 1 Year
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Sep 24, 2026, 10:49 PM EDT
Completed Phase 2 Interventional

The Effect of Thyroid Hormone on Drug Elimination in Cancer Patients

NCT00080574
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Skin Biopsy
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 24, 2026, 10:49 PM EDT
Terminated Phase 2 Interventional Results available

Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma

NCT03787303
View directory record Official record
Conditions
Metastatic Breast Cancer, Thyroid Dysfunction
Interventions
Triiodothyronine (T3)
Drug
Lead sponsor
Aultman Health Foundation
Other
Eligibility
18 Years to 105 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Sep 24, 2026, 10:49 PM EDT
Not yet recruiting Phase 2 Interventional

T4/T3 Therapy in Hypothyroidism

NCT07424183
View directory record Official record
Conditions
Hypothyroidism Primary
Interventions
Liothyronine (L-T3), Levothyroxine Sodium (LT4) Tablets, Liothyronine (LT3) placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 24, 2026, 10:49 PM EDT
Completed Phase 2 Interventional Results available

Energy Metabolism in Thyroidectomized Patients

NCT04782856
View directory record Official record
Conditions
Thyroid Goiter, Hypothyroidism, Thyroid Cancer
Interventions
Levothyroxine, Liothyronine, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 89 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Sep 24, 2026, 10:49 PM EDT
Recruiting Phase 2 Interventional

Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans

NCT05526144
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Liver Fibrosis
Interventions
Synthroid, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 24, 2026, 10:49 PM EDT
Not yet recruiting Phase 4 Interventional

Discontinuation of Low-Dose Levothyroxine in Older Adults With Subclinical Hypothyroidism

NCT07787585
View directory record Official record
Conditions
Hypothyroidism
Interventions
Levothyroxine Pill, Placebo
Drug
Lead sponsor
Spyridoula Maraka
Other
Eligibility
65 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
3
States / cities
Little Rock, Arkansas • Gainesville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 24, 2026, 10:49 PM EDT
Terminated Not applicable Interventional Results available

Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors

NCT00488644
View directory record Official record
Conditions
Hypothyroidism, Brain Tumor
Interventions
Levothyroxine, Liothyronine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 24, 2026, 10:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acute Pediatric Fracture Analgesia Study

NCT00520442
View directory record Official record
Conditions
Fracture
Interventions
ibuprofen, acetamin w codeine
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
4 Years to 18 Years
Enrollment
335 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 6, 2008 · Synced Sep 24, 2026, 10:49 PM EDT
Completed Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism

NCT05412979
View directory record Official record
Conditions
Hypothyroidism
Interventions
ST-1891, Levothyroxine
Drug
Lead sponsor
Sention Therapeutics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
39
States / cities
Greenbrae, California • Newhall, California • Denver, Colorado + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2024 · Synced Sep 24, 2026, 10:49 PM EDT
Withdrawn Phase 4 Interventional

Levothyroxine in Pregnant SLE Patients

NCT01276782
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Levothyroxine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2015 · Synced Sep 24, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers

NCT03856970
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Microgestin®, Levothyroxine, Glyburide, Digoxin, IW-3718
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2019 · Synced Sep 24, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass

NCT02320669
View directory record Official record
Conditions
Congenital Heart Defects
Interventions
Triostat, Placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Up to 5 Months
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Sep 24, 2026, 10:49 PM EDT
Withdrawn Not applicable Interventional

The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma

NCT01707056
View directory record Official record
Conditions
Thyroid Carcinoma, Hypothyroidism
Interventions
Black Coffee, Coffee with Milk, Black Tea, Water
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Leonardtown, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Sep 24, 2026, 10:49 PM EDT
Completed Phase 4 Interventional

Sequenced Treatment Alternatives to Relieve Depression (STAR*D)

NCT00021528
View directory record Official record
Conditions
Depression
Interventions
citalopram, BuproprionSR, buspirone, Lithium, mirtazapine, nortriptyline, sertraline, tranylcypromine, VenlafaxineXR, Cognitive Therapy, T3 (Triiodothyronine)
Drug · Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
41
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Chula Vista, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2009 · Synced Sep 24, 2026, 10:49 PM EDT
Completed Phase 2 Interventional Results available

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

NCT01391962
View directory record Official record
Conditions
Sarcoma, Alveolar Soft Part
Interventions
Cediranib, Sunitinib, Prochlorperazine, Promethazine, Benzodiazepine, Filgrastim, Sargramostim, Lomotil, Loperamide, Vitamin B6, Aquaphor, Acetaminophen, Levothyroxine, Warfarin
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 24, 2026, 10:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Developing Oral LT3 Therapy for Heart Failure - HFpEF

NCT04111536
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Low Triiodothyronine Syndrome
Interventions
liothyronine, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 24, 2026, 10:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Thyroid and Fat Tissue Metabolism

NCT00312715
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 24, 2026, 10:49 PM EDT
Active, not recruiting Phase 2 Interventional

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

NCT04743661
View directory record Official record
Conditions
Recurrent Medulloblastoma, Recurrent Ependymoma
Interventions
Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 24, 2026, 10:49 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Liothyronine on Energy Expenditure and Cardiovascular Function

NCT03098433
View directory record Official record
Conditions
Healthy
Interventions
Liothyronine, Levothyroxine, Placebos
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 24, 2026, 10:49 PM EDT
Withdrawn Phase 3 Interventional

Thyroxine Treatment in Premature Infants With Intraventricular Hemorrhage

NCT03390530
View directory record Official record
Conditions
Intraventricular Hemorrhage of Prematurity
Interventions
Thyroxine, Placebo
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
3 Days to 6 Days
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Sep 24, 2026, 10:49 PM EDT